# One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL

> **NCT06618313** · NA · RECRUITING · sponsor: **Beijing GoBroad Hospital** · enrollment: 8 (estimated)

## Conditions studied

- B-Cell Non-Hodgkin Lymphoma-Recurrent
- B-Cell Non-Hodgkin Lymphoma-Refractory

## Interventions

- **DRUG:** JCXH-213,an mRNA-LNP based in vivo CAR therapy

## Key facts

- **NCT ID:** NCT06618313
- **Lead sponsor:** Beijing GoBroad Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-27
- **Primary completion:** 2026-08
- **Final completion:** 2026-12
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2025-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06618313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06618313, "One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06618313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*